Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report
Sign Up to like & getrecommendations! Published in 2021 at "BMC Nephrology"
DOI: 10.1186/s12882-021-02386-y
Abstract: Background Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but potentially fatal complication. It typically presents as… read more here.
Keywords: gemcitabine dexamethasone; cisplatin therapy; cisplatin; dexamethasone cisplatin ... See more keywords
Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin Therapy in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Study Protocol.
Sign Up to like & getrecommendations! Published in 2019 at "Acta medica Okayama"
DOI: 10.18926/amo/57379
Abstract: Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. Romidepsin was launched in Japan as a consolidation therapy agent after conventional salvage chemotherapy… read more here.
Keywords: therapy; gemcitabine dexamethasone; cell lymphoma; peripheral cell ... See more keywords